Lawrence J. Murphy Appointed to Third Wave Board of Directors
News Jan 19, 2006
Third Wave Technologies Inc. has announced that Lawrence J. Murphy has joined the company’s board of directors.
Mr. Murphy, 63, brings to Third Wave’s board 30 years of business experience in strategic partnerships, mergers and acquisitions, operations, finance, law and administration.
Mr. Murphy has been an independent business consultant since 1997, providing strategic business counsel across a broad range of issues, with an emphasis on mergers and acquisitions.
He has served as the lead business advisor on significant transactions for his clients, including Jabil Circuit Inc.
He has served as a director of the company since 1989, when its revenues were approximately $100 million.
Prior to establishing his consulting business, Mr. Murphy served as executive vice president and secretary of Core Industries Inc.
He led 20 acquisition and divesture transactions involving approximately $630 million in revenue and played an important role in the refocusing of the company that resulted in a five-fold increase in its market capitalization. He was elected a director of the company in 1992.
Mr. Murphy was a certified public accountant with Deloitte & Touche and a practicing attorney before he joined Core Industries.
"Larry Murphy has a demonstrated record of leading rapid growth and creating value for customers and shareholders," said Kevin T. Conroy, president and chief executive officer of Third Wave.
"We are very pleased that Larry is joining Third Wave’s board of directors. His incisive strategic perspective and broad operational experience will be invaluable to Third Wave as we continue to drive the company’s emergence as a leader in molecular diagnostics."
Mr. Murphy will serve on Third Wave’s audit and compensation committees.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.